Examples of Product Sales Milestone #1 in a sentence
Sales in subsequent periods are not used to calculate Product Sales Milestone #1.
On July 5, 2016 Sanofi disclosed that, based upon actual sales of Lemtrada® in Qualifying Major Markets and in other markets during the respective applicable periods since the Product Launch, Product Sales Milestone #1 has not been met.
On October 29, 2015, Sanofi disclosed that, based on actual sales trends to date, Sanofi does notexpect that Product Sales Milestone #1 will be met.
For example, while the total payment under the CVR to Genzyme shareholders if Product Sales Milestone #1 were reached would be $2.00, discounting that future cash flow (estimated to be achieved in the third quarter of 2013) by 8.5% and then multiplying by the probability of 80% that the milestone would be achieved, purportedly results in an “illustrative midpoint probability-adjusted intrinsic value” of $1.28.
Product Sales Milestone #1: CVR holders are entitled to receive $2 per CVR in the event net sales for Lemtrada total $400 million or more on a global basis during specified periods following product launch.
Appellants’ contention that Professor Laycock’s approval of a much broader bill somehow supports their attack on a narrower spending enactment is puzzling.
Based upon actual sales of Lemtrada® in Qualifying Major Markets and in other markets during the respective applicable periods since the Product Launch, Product Sales Milestone #1 was not met.
A payment of $4.00 per CVR will be made if sales in any period of four consecutive calendar quarters during the term of the CVR Agreement equal or exceed $2,300,000,000 (excluding any quarter in which sales were used to determine whether Product Sales Milestone #1 or #2 was achieved).• Product Sales Milestone #4.
As Sanofi’s CEO, Christopher Viehbacher, stated in an investor call on October 28, 2014, “if the FDA does not approve a product straight away, even if you get it approved elsewhere, there is still a ‘waiting to see what the FDA does’.” Sanofi’s failure to use Diligent Efforts to achieve the Approval Sales Milestone has led Sanofi to miss the Product Sales Milestone #1, and continues to adversely affect Sanofi’s ability to meet each of the other Product Sales Milestones.
Had Sanofi and Genzyme used efforts and employed the resources normally used by companies in the pharmaceutical business to commercialize and promote Lemtrada, including but not limited to making appropriate expenditures to commercialize and promote Lemtrada, the Product Sales for Lemtrada would have been significantly higher, and Product Sales Milestone #1 would have been met as early as the second quarter of 2015, and no later than the third quarter of 2015.